Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Transaction in Own Shares - CORRECTION
-
Patton Creates Revolutionary 100 Gigabit Data Diode SFP Module
-
Form 8.5 (EPT/RI)-NCC Group plc
-
Viridien: Information on the total number of voting rights and shares
-
Michael Owen joins Casino.org as Exclusive UK & Ireland Affiliate Ambassador for 2026
-
Form 8.5 (EPT/RI)-Dowlais Group plc
-
Bitget Opens TradFi Trading to All Users After Record-Breaking Beta Demand
-
TRREB: 2025 Ends with More Affordable Market and Paves the Way for Year of Recovery
-
LIfT BioSciences Announces CEO Transition to Drive Next Phase of Growth with Neutrophil-based Therapies
-
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies
-
Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical
-
MEXC Launches Spot DCA to Support Automated Investment Strategies
-
Form 8.5 (EPT/RI) - PPHE Hotel Group Limited
-
Form 8.5 (EPT/RI) - Kore Potash Plc
-
Form 8.5 (EPT/RI) - Greencore Group Plc
-
Elis: Disclosure of the number of shares forming the capital and of the total number of voting rights as of 31 12 2025
-
Kristian Teär steps down as CEO of Bang & Olufsen, CFO Nikolaj Wendelboe appointed interim CEO. Preliminary Q2 2025/26 key financials announced, and FY 2025/26 outlook narrowed
-
Correction: JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
-
Humanoid Global Announces Strategic Investment in MBody AI, Developer of an Embodied AI Autonomy Platform
-
Acronis Appoints Jo Holliday as General Manager for United Kingdom and Ireland
-
Repayments, Realkredit Danmark A/S
-
Ice and Snow as a Bridge to Global Dialogue, Charting a New Chapter of Cooperative Development: the “Global Mayors Dialogue · Harbin” Kicked Off on January 6
-
Immortal Dragons Comments on Longevity Regulation and Investment Trends Following FT Podcast Appearance
-
Relation Announces Strategic Collaboration with Deerfield Management to Advance Novel Therapeutics
-
Minuteman Press Franchise in Boksburg Acquires 31-Year Business Wilpro Printers, Biggest Acquisition for Minuteman Press in South Africa
-
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
-
Alm. Brand Group newsletter ahead of Q4 results
-
G. Kudarauskas Appointed Chief Financial Officer of Utenos Trikotazas
-
Offentliggørelse af prospekt for Investeringsforeningen Nordea Invest
-
Increase of Share Capital in Connection with Realization of the Option Programme and Subscription Results
-
Nilfisk Board recommends shareholders accept takeover offer from Freudenberg
-
Expansion of Car Trade Activities in Estonia through Acquisition of Shareholdings
-
Telia Lietuva to reorganise Technology unit in digital shift
-
Publication of statement by the Board of Directors in respect of the takeover offer from Freudenberg to the shareholders of Nilfisk Holding
-
Publication of offer document in respect of the takeover offer from Freudenberg to the shareholders of Nilfisk Holding
-
Major shareholder announcement – Jyske Bank A/S
-
Bavarian Nordic Launches Planned Share Buy-Back Program
-
B2BROKER’s Report Is Live: 63% Brokers Launch with Integrated Stack in Just 10 Days
-
Orrön Energy secures grid connections for six projects in the UK and obtains municipal approval for additional projects in Germany
-
NBPE Announces Transaction in Own Shares
-
Transaction in Own Shares
-
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
-
Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections
-
FLSmidth: Transactions under share buy-back programme
-
Vetted Prop Firms Partners with SabioTrade to Unlock Exclusive Crypto Prop Trading Opportunities
-
Technip Energies awarded two large contracts by BPCL for new units at Bina and Mumbai refineries in India
-
Start of Day Message
-
JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
-
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
-
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
